Raltitrexed

雷替曲塞

Report date: 2026/02/26 20:00:22
NME

Base Information

Drug NameRaltitrexed
Drug Alias Name雷替曲噻Raltitrexedum替特噻TomudexNSC-639186 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThymidylate synthase inhibitors
TargetsThymidylate synthase
Therapy Area/IndicationsRectal NeoplasmsColorectal NeoplasmsLeukemia, Myeloid, Acute +[5] 
Global Approved IndicationsColorectal Neoplasms
Approved Indications in ChinaColorectal Neoplasms
Original Approved Country/TerritoryCanada
Original Approved Date1996/11/18
Country/TerritoryCanadaUnited StatesTurkey +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca PlcPfizer IncInstitute Of Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca PlcNational Cancer InstituteFudan University
Active IndicationsColorectal Neoplasms
Inactive IndicationsRectal NeoplasmsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 

Other Information

ATC CodeL01BA03
Related LinksWikipediaDrugBankKEGG